ILLUMINATE: Efficacy and Safety of Durvalumab/ Tremelimumab and Chemotherapy in EGFR-Mutant NSCLC Following Progression on EGFR Inhibitors

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [1] ILLUMINATE: Efficacy and Safety of DurvalumabTremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors
    Lee, C.
    Liao, B-C.
    Subramaniam, S.
    Chiu, C. -H.
    Mersiades, A.
    Ho, C. -C.
    Brown, C.
    Lai, C. -L.
    Hughes, B. G. M.
    Yang, T. -Y.
    O'Byrne, K.
    Luo, Y. -H.
    Yip, S.
    Ho, C. -L.
    Bray, V.
    Su, W. -C.
    Moore, M.
    Feng, W. -L.
    Bai, Y. -Y.
    Stockler, M.
    Solomon, B.
    John, T.
    Yang, J. C. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S63 - S63
  • [2] A phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-small cell lung cancer following progression on EGFR tyrosine kinase inhibitors (ILLUMINATE)
    Lee, Chee Khoon
    Mersiades, Antony
    Mitchell, Jenna
    Brown, Chris
    Jurkovic, Hannora
    Solomon, Ben
    John, Thomas
    Stockler, Martin
    Yang, James Chi-Hsin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 197 - 198
  • [3] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [4] Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
    Piotrowska, Zofia
    Liu, Stephen V.
    Muzikansky, Alona
    Marcoux, Nicolas
    Banwait, Mandeep
    Stevens, Sara
    Goodwin, Kelly
    Lafferty, Tracey E.
    Ackil, Jennifer
    Krueger, Elizabeth A.
    Heist, Rebecca Suk
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Hata, Aaron N.
    Shaw, Alice Tsang
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC
    Bauman, Jessica
    Borghaei, Hossein
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 894 - 896
  • [6] Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
    Neal, Joel W.
    Hausrath, Daniel
    Wakelee, Heather A.
    Cunanan, Kristen
    Liu, Stephen V.
    Banwait, Mandeep
    Sequist, Lecia V.
    Stirling, Kevin
    Piotrowska, Zofia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
    Wang, Kaiwen
    Du, Robyn
    Myall, Nathaniel J.
    Lewis, Whitney E.
    Uy, Natalie
    Hong, Lingzhi
    Skoulidis, Ferdinandos
    Byers, Lauren A.
    Tsao, Anne
    Cascone, Tina
    Pozadzides, Jenny
    Tu, Janet
    Negrao, Marcelo, V
    Gibbons, Don L.
    Park, Keunchil
    Rinsurongkawong, Waree
    Lee, J. Jack
    Gandara, David
    Behl, Deepti
    Shu, Catherine A.
    Riess, Jonathan W.
    Baik, Christina
    Wakelee, Heather A.
    Vaporciyan, Ara A.
    Heymach, John, V
    Zhang, Jianjun
    Le, Xiuning
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 500 - 506
  • [8] Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM)
    Planchard, D.
    Barlesi, F.
    Gomez-Roca, C.
    Mazieres, J.
    Varga, A.
    Greillier, L.
    Chaput, N.
    Parlavecchio, C.
    Malekzadeh, K.
    Ngocamus, M.
    Zahi, S.
    Besse, B.
    Lanoy, E.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC "
    Chen, Ching-Yi
    Wang, Guo-Sheng
    Wei, James Cheng-Chung
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05) : e6 - e7
  • [10] Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC An Open-Label Phase 2 Trial (ILLUMINATE)
    Lee, Chee Khoon
    Liao, Bin-Chi
    Subramaniam, Shalini
    Chiu, Chao-Hua
    Mersiades, Antony
    Ho, Chao-Chi
    Brown, Chris
    Lai, Chun-Liang
    Hughes, Brett G. M.
    Yang, Tsung-Ying
    O'Byrne, Ken
    Luo, Yung-Hung
    Yip, Sonia
    Ho, Ching-Liang
    Bray, Victoria
    Su, Wu-Chou
    Moore, Melissa
    Feng, Wei-Lien
    Bai, Ya-Ying
    Ford, Kate
    Cummins, Michelle M.
    Stockler, Martin R.
    Solomon, Benjamin J.
    John, Thomas
    Yang, James Chih-Hsin
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (02):
12345